NasdaqGM:NAMSBiotechs
NewAmsterdam Pharma (NAMS) Valuation Check After Earnings Beat And Obicetrapib Pipeline Milestones
NewAmsterdam Pharma (NAMS) drew fresh attention after reporting first quarter 2026 results that came in ahead of revenue and earnings estimates, while management highlighted several upcoming clinical and regulatory milestones.
See our latest analysis for NewAmsterdam Pharma.
The stock reacted sharply to the update, with a 1 day share price return of 12.46% and a 7 day share price return of 22.02%. This comes even though the year to date share price return is slightly negative, while the 1...